Takeda Deepens Links As London Touts Life Science Credentials
This article was originally published in PharmAsia News
The UK, and London in particular, supported by its mayor, is making a major push in Japan for life sciences collaboration and investment, as part of which a new academic research collaboration involving Takeda has been unveiled that deepens the Japanese firm's UK links.
You may also be interested in...
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
While Astellas, like many other large pharma firms globally, is pursuing the adoption of digital technologies across multiple disciplines, it is aiming to keep patients at the center of its initiatives and also sees a strong need for the "best mix" of the human touch and technology.
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.